港股異動 | 中手遊(0302.HK)漲超9% 新射鵰羣俠傳港澳台今日正式上線
格隆匯1月21日丨中手遊(0302.HK)高開高走,現漲9.12%報3.35港元,暫成交2億港元,最新總市值84億港元。據悉,帶着國內成功的發行經驗,《新射鵰羣俠傳》今日正式登陸港澳台地區。傑富瑞曾發研報指,中手遊是中國領先的網絡遊戲開發商之一,擁有超過10年的發行和開發運營歷史。中手遊於2020年下半年推出了不少遊戲,包括《新射鵰羣俠傳之鐵血丹心》和《龍城傳奇》,該行預計這兩款遊戲將會取得成功,並預計公司2020年全年營收將達41%的同比增幅,其中下半年營收將有49%的環比增幅,增量營收主要來自這兩款遊戲。給予中手遊“買入”評級,目標價4.1港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.